Literature DB >> 378866

Isolation and characterization of lymphocytes and macrophages from solid, malignant human tumours.

J L Svennevig, M Lövik, H Svaar.   

Abstract

In mechanically prepared cell suspensions from 17 solid, malignant human tumours, 0.5-5.0% (mean 2.0%) lymphocytes and 1.0-28.0% (mean 7.4+) macrophages were found. Mononuclear cells (MC) were isolated using the Böyum technique. From each biopsy weghing 1-4 g, on average, 1.3 x 10(6) lymphocytes and 0.8 x 10(6) macrophages were recovered. The tumour-infiltrating lymphocytes (TIL) were characterized with regard to T and B markers. The proportion of TIL-forming rosettes with SRBC (T cells) was 43%, which was significantly less than for peripheral blood lymphocytes (PBL) from cancer patients (58%), or normal controls (80%), On average, 15% of the TIL were B cells, whereas 42% had no T- or B-cell markers. Macrophages (TIM) were identified by non-specific esterase staining and phagocytosis. In four cases the tumour cells were also stained with alpha-naphthyl butyrate. Corresponding findings were made on esterase-stained cryostat sections from four tumours. Macrophages were found within and around the tumour tissues, occasionally localized to necrotic areas, but in most cases with no sign of necrosis of the surrounding cells. In some tumour cell suspensions typical clusters of lymphocytes and macrophages were seen. Total lymphocytes and T-cell were markedly reduced inthe peripheral blood of cancer patients, whereas total monocyte counts were within the normal range.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378866     DOI: 10.1002/ijc.2910230507

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.

Authors:  R P Negus; G W Stamp; J Hadley; F R Balkwill
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts.

Authors:  M K Dabbous; S M North; L Haney; D A Tipton; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1995-01       Impact factor: 5.150

3.  Association of macrophages detected with monoclonal antibody 25 F 9 with progression and pathobiological classification of gastric carcinoma.

Authors:  G Heidl; P Davaris; G Zwadlo; M S Jagoda; S Düchting; E Bierhoff; T Grüter; V Krieg; C Sorg
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 4.  Collagenolytic mechanisms in tumor cell invasion.

Authors:  D E Woolley
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

5.  Differentiation of macrophages from Lewis lung carcinoma tumour cells in tissue sections by their alpha-naphthyl butyrate esterase activity.

Authors:  R Brown; M Wolman
Journal:  Histochem J       Date:  1981-11

6.  The analysis of mononuclear cell infiltrations in colorectal adenocarcinoma.

Authors:  B Koch; J Giedl; P Hermanek; J R Kalden
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

7.  Lymphoid infiltration and prognosis in colorectal carcinoma.

Authors:  J L Svennevig; O C Lunde; J Holter; D Bjørgsvik
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

8.  Canine transmissible venereal sarcoma: distribution of T and B lymphocytes in blood, draining lymph nodes and tumours at different stages of growth.

Authors:  J P Chandler; T J Yang
Journal:  Br J Cancer       Date:  1981-10       Impact factor: 7.640

9.  Cells bearing Fc receptors in human malignant solid tumours.

Authors:  J L Svennevig; T R Andersson
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

10.  Macrophage content and colony-forming potential in mouse mammary carcinomas.

Authors:  J R Nash; J E Price; D Tarin
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.